Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
LIFECORE BIOMEDICAL, INC. (LNDC)
|
Add to portfolio |
|
|
|
| Price: |
$11.02
| | Metrics |
| OS: |
30.3
|
M
| |
-231
|
% ROE
|
| Market cap: |
$334
|
M
| |
-37
|
% ROIC
|
|
Net debt:
|
$112
|
M
| |
|
|
|
EV:
|
$446
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($71.5)
|
M
| |
|
|
|
EBIT
|
($74.9)
|
M
| |
|
|
| EPS |
($4.82)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 10/10/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/22/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 08/15/2023 |
SC 13D/A
| Cove Street Capital, LLC reports a 5.2% stake in LIFECORE BIOMEDICAL, INC |
| 08/14/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 1.8% stake in LIFECORE BIOMEDICAL, INC |
| 06/30/2023 |
SC 13G
| Greenhaven Road Investment Management, L.P. reports a 6.3% stake in LIFECORE BIOMEDICAL, INC. |
| 06/28/2023 |
SC 13D/A
| 22NW Fund, LP reports a 10% stake in Lifecore Biomedical, Inc. |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | May-29-22 | May-30-21 | May-31-20 | May-26-19 | May-27-18 | May-28-17 | May-29-16 | May-31-15 |
| Revenues | 185.8 | 171.5 | 160.1 | 557.6 | 524.2 | 469.8 | 476.9 | 539.3 |
| Revenue growth | 8.3% | 7.2% | -71.3% | 6.4% | 11.6% | -1.5% | -11.6% | 13.1% |
| Cost of goods sold | 135.4 | 121.1 | 120.7 | 476.6 | 445.9 | 390.6 | 410.1 | 473.9 |
| Gross profit | 50.4 | 50.5 | 39.4 | 81.0 | 78.3 | 79.2 | 66.8 | 65.4 |
| Gross margin | 27.1% | 29.4% | 24.6% | 14.5% | 14.9% | 16.9% | 14.0% | 12.1% |
| Selling, general and administrative | 46.1 | 37.7 | 40.7 | 62.1 | 52.0 | 52.5 | 46.2 | 40.0 |
| Research and development | 7.8 | 7.4 | 7.6 | 11.5 | 12.8 | 9.5 | 7.2 | 7.0 |
| EBITA | -48.3 | 6.8 | -17.3 | 9.0 | 14.6 | 18.1 | 14.8 | 19.3 |
| EBITA margin | -26.0% | 4.0% | -10.8% | 1.6% | 2.8% | 3.9% | 3.1% | 3.6% |
| Amortization of intangibles | 1.4 | 1.4 | 1.5 | 1.5 | 1.0 | 0.9 | 0.9 | 0.9 |
| EBIT | -49.7 | 5.4 | -18.8 | 7.5 | 13.6 | 17.2 | 13.9 | 18.5 |
| EBIT margin | -26.7% | 3.1% | -11.8% | 1.3% | 2.6% | 3.7% | 2.9% | 3.4% |
| Pre-tax income | -69.5 | -11.5 | -30.6 | 3.6 | 16.4 | 14.2 | -19.7 | 21.5 |
| Income taxes | -5.9 | -1.9 | -8.8 | 1.5 | -9.4 | 4.0 | -7.7 | 7.7 |
| Tax rate | 8.6% | 16.6% | 28.6% | 41.7% | | 28.5% | 39.1% | 36.1% |
| Earnings from continuing ops | -63.5 | -9.6 | -21.9 | 4.2 | 51.4 | 10.0 | -24.2 | 13.5 |
| Earnings from discontinued ops | -51.2 | -23.1 | -16.3 | -1.7 | -0.8 | 0.5 | 0.5 | |
| Net income | -114.7 | -32.7 | -38.2 | 2.5 | 50.6 | 10.6 | -23.6 | 13.5 |
| Net margin | -61.7% | -19.0% | -23.9% | 0.5% | 9.7% | 2.3% | -5.0% | 2.5% |
| |
| Diluted EPS | ($2.16) | ($0.33) | ($0.75) | $0.15 | $1.84 | $0.36 | ($0.89) | $0.50 |
| Shares outstanding (diluted) | 29.5 | 29.3 | 29.2 | 28.6 | 27.9 | 27.7 | 27.0 | 27.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|